Dhizhayo Wart Remover

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the removal of common warts characterized by a rough, cauliflower-like appearance.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The affected area should be washed thoroughly, and soaking in warm water for approximately 5 minutes may facilitate this process. After cleansing, the area must be dried completely. A small amount of the medication should then be applied to cover each wart, ensuring that it is allowed to dry. This application should be repeated twice daily as necessary, with treatment continuing for a maximum duration of 12 weeks.

Contraindications

Use of this product is contraindicated in the following situations:

Application on irritated or infected skin, or on areas exhibiting redness, is not recommended due to the potential for exacerbating the condition.

Patients with diabetes or poor blood circulation should avoid use, as these conditions may impair healing and increase the risk of adverse effects.

The product should not be applied to birthmarks, warts with hair growth, or moles, as these may present a risk of irritation or other complications.

Warnings and Precautions

The product is intended for external use only and should not come into contact with the eyes. In the event of accidental exposure to the eyes, it is imperative to rinse thoroughly with water for at least 15 minutes. Additionally, users should avoid inhaling vapors associated with the product to prevent respiratory irritation.

Healthcare professionals should advise patients who are pregnant or breastfeeding to consult with a qualified health professional prior to using this product, ensuring that any potential risks are adequately assessed.

In cases of accidental ingestion, it is crucial to seek immediate medical assistance or contact a Poison Control Center without delay. Prompt action is essential to mitigate any potential health risks.

Patients are advised to discontinue use of the product and consult a healthcare provider if discomfort persists. This precaution is vital to ensure the safety and well-being of the user.

Side Effects

Patients using this product should be aware that it is intended for external use only. Care should be taken to avoid contact with the eyes; in the event of contact, it is recommended to rinse the eyes with water for 15 minutes. Additionally, patients should avoid inhaling vapors associated with the product.

In the case of persistent discomfort, patients are advised to discontinue use and consult a healthcare professional. This precaution is important to ensure safety and address any potential adverse reactions that may arise during use.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there are no known interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Dhizhayo Wart Remover (salicylic acid 17% wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is essential to evaluate the potential risks and benefits in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may indicate an overdose. These may include, but are not limited to, increased severity of known side effects, unusual behavioral changes, or any other atypical clinical manifestations.

Management of an overdose should be guided by the clinical presentation of the patient. Supportive care is paramount, and symptomatic treatment should be initiated as necessary. It is recommended that healthcare professionals consult local poison control centers or relevant toxicology resources for specific guidance on the management of overdose cases.

In summary, while specific overdosage information is not available, healthcare professionals should exercise caution, remain observant for potential overdose symptoms, and implement appropriate management strategies in the event of an overdose.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical help or contact a Poison Control Center if the product is swallowed.

Patients should be informed that the product should not be applied to irritated or infected skin, or to reddened areas, particularly if they are diabetic or have poor blood circulation. Additionally, it should not be used on birthmarks, warts with hair growth, or moles.

Healthcare providers should instruct patients to stop using the product and consult a doctor if discomfort persists after application.

For patients who are pregnant or breastfeeding, it is essential to recommend consulting a health professional before using the product to ensure safety for both the patient and the child.

Storage and Handling

The product is supplied in a tube format, with specific handling and storage requirements to ensure its integrity and efficacy. It should be stored at room temperature, away from direct light exposure. To maintain the product's quality, the tube must be kept tightly closed when not in use. Additionally, it is important to discard the product after opening if it is not used within the specified time frame, which is not detailed in the provided information.

Additional Clinical Information

The medication is administered topically. Clinicians should instruct patients to wash the affected area, potentially soaking it in warm water for five minutes to aid in the process. After drying the area thoroughly, a small amount of the medication should be applied to cover each wart, allowing it to dry. This application should be repeated twice daily as needed, for a maximum duration of 12 weeks.

No additional information is available regarding laboratory tests, abuse potential, patient counseling, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Dhizhayo Wart Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)